NCT03523182

Brief Summary

Background: In developing countries, micronutrient deficiency in infants is associated with growth faltering, morbidity, and delayed motor development. One of the potentially low-cost and sustainable solutions is to use locally producible food for the home fortification of complementary foods. Objective: The objectives are to test the hypothesis that locally producible spirulina platensis supplementation would achieve the following: 1) increase infant physical growth; 2) reduce morbidity; and 3) improve motor development. Design: 501 Zambian infants are randomly assigned into a control (CON) group or a spirulina (SP) group. Children in the CON group (n=250) receive a soya-maize-based porridge for 12 months, whereas those in the SP group (n=251) receive the same food but with the addition of spirulina. The change in infants' anthropometric status, morbidity, and motor development over 12 months are assessed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
501

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2016

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 19, 2018

Completed
25 days until next milestone

First Posted

Study publicly available on registry

May 14, 2018

Completed
Last Updated

February 11, 2019

Status Verified

February 1, 2019

Enrollment Period

1.2 years

First QC Date

April 19, 2018

Last Update Submit

February 7, 2019

Conditions

Keywords

Micronutrient supplementationHome fortificationSpirulinaZambia

Outcome Measures

Primary Outcomes (2)

  • Change from baseline in height-for-age z-scores (HAZ) at 32 month follow up

    Primary outcome is changes in HAZ. Height of the infants is transformed to standardized scores using the World Health Organization (WHO) Multicentre Growth Standards

    Height of the infants are measured by experienced field workers at at 0, 6, and 12 month. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018) survey.

  • Child development

    Study children will be assessed at 32 month follow up (January 2018) using the Malawi Development Assessment Tool (MDAT) instrument. Scores will be standardized within the study sample for analysis. Scores of children in treatment group will be compared with children in comparison group to determine differences.

    At 32 month follow up (January 2018) survey

Secondary Outcomes (7)

  • Change from baseline in weight-for-age z-scores (WAZ) at 32 month follow up

    Weight of the infants are measured at 0, 6, and 12 month by experienced field workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)

  • Change from baseline in pneumonia incidence at 32 month follow up

    Data on pneumonia indicators were collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)

  • Change from baseline in cough incidence at 32 month follow up

    Data on cough morbidity indicators are collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)

  • Change from baseline in severe high fever incidence at 32 month follow up

    Data are collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)

  • Change from baseline in fever incidence at 32 month follow up

    Data are collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)

  • +2 more secondary outcomes

Study Arms (2)

Spirulina (SP)

EXPERIMENTAL

Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.

Dietary Supplement: SpirulinaDietary Supplement: Control

Control (CON)

ACTIVE COMPARATOR

Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.

Dietary Supplement: Control

Interventions

SpirulinaDIETARY_SUPPLEMENT

Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa. Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina. We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend.

Spirulina (SP)
ControlDIETARY_SUPPLEMENT

Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.

Control (CON)Spirulina (SP)

Eligibility Criteria

Age6 Months - 18 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • All infants were eligible for the study if they are between 6 and 18 month of age

You may not qualify if:

  • Non-singleton birth infants were excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Programme Against Malnutrition

Mansa, Luapura, Zambia

Location

MeSH Terms

Conditions

Growth DisordersThinnessPneumonia, PneumocystisCoughMalariaFeverPsychomotor Disorders

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsBody WeightSigns and SymptomsLung Diseases, FungalMycosesBacterial Infections and MycosesInfectionsPneumocystis InfectionsRespiratory Tract InfectionsPneumoniaLung DiseasesRespiratory Tract DiseasesRespiration DisordersSigns and Symptoms, RespiratoryProtozoan InfectionsParasitic DiseasesMosquito-Borne DiseasesVector Borne DiseasesBody Temperature ChangesNeurobehavioral ManifestationsNeurologic ManifestationsNervous System Diseases

Study Officials

  • Kazuya Masuda, PhD

    Hitotsubashi University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 19, 2018

First Posted

May 14, 2018

Study Start

March 1, 2015

Primary Completion

April 30, 2016

Study Completion

January 30, 2018

Last Updated

February 11, 2019

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will not share

Locations